Physician profile
Amisha Jain
NPI 1306171665
$925.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $245 · 2021: $125 · 2022: $96.47.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $104.04 | 2019-2021 | |
| Sanofi Pasteur INC. | $96.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $91.22 | 2019-2020 | |
| Philips North America LLC | $89.24 | 2020-2021 | |
| Kaleo, INC. | $80.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.83 | 2019-2020 | |
| Abbvie INC. | $61.88 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $60.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.48 | 2019-2020 | |
| Covis Pharma Gmbh | $55.09 | 2019 | |
| Advanced Respiratory, INC | $44.27 | 2021 | |
| Genentech USA, INC. | $36.58 | 2019 | |
| Allergan, INC. | $28.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.46 | 2019 | |
| Mylan Specialty L.P. | $15.26 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amisha Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.